Tecnología Nanopore para la secuenciación de DNA

Nanopore-based sequencer will open the path to the fourth-generation DNA sequencing technology. The main differences between this technique and the previous ones are: DNA molecule that will be sequenced does not need a previous amplification step, is not necessary any type of specific label both molecular adaptors, and it has been abolished enzymatic process in the nucleotide sequence identification event. These differences have as result a more economic method since don’t spend the necessary reagents for the previous techniques, furthermore it lets to sequence samples with a low DNA concentration. This technique is based in the use of a membrane with a biologic nanopore inserted in it whereby the molecule to analyze (analyte) it made to pass, this membrane is placed between two reservoirs containing ions, when an external volatage is applied in both sides this lead to an ion current through the nanopore. When an analyte cross the nanopore the ion current is modified, that modification in the amplitude and duration of ion current determine the physical and chemical properties of that analyte. By means of subsequent statistical analyzes it can be determined to what sequence own this ion current blockade patterns. More used nanopores are the biologic ones, although they are working to develop synthetic nanopores. The main biologic nanopores are: α-Hemolysin from Staphylococcus aureus (α-HL), Mycobacterium smegmatis porin A (MspA) and bacteriophage phi29 pore (phi29). Α-HL and MspA have in their narrowest point a diameter similar to nucleotide size, they are functional at high temperature both wide range of pH (2-12) but MspA is able to read four nucleotide at the same time while α- HL just can read one by one. Finally, phi29 present a bigger diameter what let to get information about DNA spatial conformation and their interaction with proteins (Feng et al., 2015). Nowaday Oxford Nanopore Technologies (ONT) is the only company which has developed Nanopore technology; they have two devices available to sequencing (PromethION and MinION). The MinION is a single-use DNA sequencing device with the size of a USB memory with a total of 3000 nanopores that can sequence until 200kb. The PrometheION is big size sequencer that own 48 different cells, what let to sequence different samples at the same time, with a total of 144.000 nanopores and reading of several megabases (https://www.nanoporetech.com/). The high processivity and low cost become this technique in a great option to massive- sequencing.

RGS14 (414)-mediated prevention of an episodic memory loss: a study of molecular mechanism

A large proportion of human populations suffer memory impairments either caused by normal aging or afflicted by diverse neurological and neurodegenerative diseases. Memory enhancers and other drugs tested so far against memory loss have failed to produce therapeutic efficacy in clinical trials and thus, there is a need to find remedy for this mental disorder. In search for cure of memory loss, our laboratory discovered a robust memory enhancer called RGS14(414). A treatment in brain with its gene produces an enduring effect on memory that lasts for lifetime of rats. Therefore, current thesis work was designed to investigate whether RGS14(414) treatment can prevent memory loss and furthermore, explore through biological processes responsible for RGS-mediated memory enhancement. We found that RGS14(414) gene treatment prevented episodic memory loss in rodent models of normal aging and Alzheimer´s disease. A memory loss was observed in normal rats at 18 months of age; however, when they were treated with RGS14(414) gene at 3 months of age, they abrogated this deficit and their memory remained intact till the age of 22 months. In addition to normal aging rats, effect of memory enhancer treatment in mice model of Alzheimer´s disease (AD-mice) produced a similar effect. AD-mice subjected to treatment with RGS14(414) gene at the age of 2 months, a period when memory was intact, showed not only a prevention in memory loss observed at 4 months of age but also they were able to maintain normal memory after 6 months of the treatment. We posit that long-lasting effect on memory enhancement and prevention of memory loss mediated through RGS14(414) might be due to a permanent structural change caused by a surge in neuronal connections and enhanced neuronal remodeling, key processes for long-term memory formation. A neuronal arborization analysis of both pyramidal and non-pyramidal neurons in brain of RGS14(414)-treated rats exhibited robust rise in neurites outgrowth of both kind of cells, and an increment in number of branching from the apical dendrite of pyramidal neurons, reaching to almost three times of the control animals. To further understand of underlying mechanism by which RGS14(414) induces neuronal arborization, we investigated into neurotrophic factors. We observed that RGS14 treatment induces a selective increase in BDNF. Role of BDNF in neuronal arborization, as well as its implication in learning and memory processes is well described. In addition, our results showing a dynamic expression pattern of BDNF during ORM processing that overlapped with memory consolidation further support the idea of the implication of this neurotrophin in formation of long-term memory in RGS-animals. On the other hand, in studies of expression profiling of RGS-treated animals, we have demonstrated that 14-3-3ζ protein displays a coherent relationship to RGS-mediated ORM enhancement. Recent studies have demonstrated that the interaction of receptor for activated protein kinase 1 (RACK1) with 14-3-3ζ is essential for its nuclear translocation, where RACK1-14-3-3ζ complex binds at promotor IV region of BDNF and promotes an increase in BDNF gene transcription. These observations suggest that 14-3-3ζ might regulate the elevated level of BDNF seen in RGS14(414) gene treated animals. Therefore, it seems that RGS-mediated surge in 14-3-3ζ causes elevated BDNF synthesis needed for neuronal arborization and enhanced ORM. The prevention of memory loss might be mediated through a restoration in BDNF and 14-3-3ζ protein levels, which are significantly decreased in aging and Alzheimer’s disease. Additionally, our results demonstrate that RGS14(414) treatment could be a viable strategy against episodic memory loss.